DK2931030T4 - Polynukleotider, der koder for graver-antistoffer med humane idiotyper, og dyr, der omfatter disse - Google Patents

Polynukleotider, der koder for graver-antistoffer med humane idiotyper, og dyr, der omfatter disse Download PDF

Info

Publication number
DK2931030T4
DK2931030T4 DK13843056.6T DK13843056T DK2931030T4 DK 2931030 T4 DK2931030 T4 DK 2931030T4 DK 13843056 T DK13843056 T DK 13843056T DK 2931030 T4 DK2931030 T4 DK 2931030T4
Authority
DK
Denmark
Prior art keywords
graver
antibodies
animals
polynucleotides encoding
human idiotypes
Prior art date
Application number
DK13843056.6T
Other languages
English (en)
Other versions
DK2931030T3 (da
Inventor
Marianne Bruggemann
Roland Buelow
Michael J Osborn
Biao Ma
Original Assignee
Omniab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50935093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2931030(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Omniab Inc filed Critical Omniab Inc
Publication of DK2931030T3 publication Critical patent/DK2931030T3/da
Application granted granted Critical
Publication of DK2931030T4 publication Critical patent/DK2931030T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK13843056.6T 2012-12-14 2013-12-13 Polynukleotider, der koder for graver-antistoffer med humane idiotyper, og dyr, der omfatter disse DK2931030T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737371P 2012-12-14 2012-12-14
PCT/US2013/075157 WO2014093908A2 (en) 2012-12-14 2013-12-13 Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same

Publications (2)

Publication Number Publication Date
DK2931030T3 DK2931030T3 (da) 2020-08-03
DK2931030T4 true DK2931030T4 (da) 2024-04-22

Family

ID=50935093

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19204021.0T DK3653049T5 (da) 2012-12-14 2013-12-13 Polynukleotider, der koder for gnaverantistoffer med humane idiotyper, og dyr, der omfatter disse
DK13843056.6T DK2931030T4 (da) 2012-12-14 2013-12-13 Polynukleotider, der koder for graver-antistoffer med humane idiotyper, og dyr, der omfatter disse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK19204021.0T DK3653049T5 (da) 2012-12-14 2013-12-13 Polynukleotider, der koder for gnaverantistoffer med humane idiotyper, og dyr, der omfatter disse

Country Status (20)

Country Link
US (2) US9475859B2 (da)
EP (3) EP2931030B2 (da)
JP (1) JP6705650B2 (da)
KR (3) KR20210040189A (da)
CN (2) CN104994729B (da)
AU (2) AU2013358958B2 (da)
CA (1) CA2895144C (da)
CY (1) CY1123215T1 (da)
DK (2) DK3653049T5 (da)
ES (2) ES2963516T3 (da)
FI (2) FI2931030T4 (da)
HR (2) HRP20231356T1 (da)
HU (2) HUE050930T2 (da)
IL (2) IL279716B1 (da)
LT (2) LT3653049T (da)
PL (2) PL3653049T3 (da)
PT (2) PT3653049T (da)
SG (1) SG11201504676VA (da)
SI (2) SI3653049T1 (da)
WO (1) WO2014093908A2 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2311874T1 (sl) 2004-07-22 2017-12-29 Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics Vezavne molekule
US10993420B2 (en) * 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
JP6641379B2 (ja) * 2014-10-22 2020-02-05 クレシェンド・バイオロジックス・リミテッド トランスジェニックマウス
KR102530821B1 (ko) * 2014-12-19 2023-05-10 리제너론 파마슈티칼스 인코포레이티드 단일 단계 다중 표적화를 통한 표적화된 유전자 변형을 위한 방법 및 조성물
PE20180802A1 (es) 2015-08-05 2018-05-09 Janssen Biotech Inc Anticuerpos anti-cd154 y metodos de uso de estos
US10072088B2 (en) 2015-08-17 2018-09-11 Janssen Pharmaceutica, Nv Anti-BCMA antibodies and uses thereof
CR20180177A (es) 2015-09-30 2018-06-22 Janssen Biotech Inc Anticuerpos agonistas que se unen específicamente a cd40 humana y método de uso
AU2016350705A1 (en) 2015-11-02 2018-05-17 Janssen Pharmaceutica Nv Anti-IL1RAP antibodies, bispecific antigen binding molecules that bind IL1RAP and CD3, and uses thereof
HUE061619T2 (hu) 2016-06-03 2023-07-28 Regeneron Pharma Exogén terminális dezoxinukleotid-transzferázt expresszáló rágcsálók
CA3029209A1 (en) * 2016-06-21 2017-12-28 Teneobio, Inc. Cd3 binding antibodies
IL264941B2 (en) 2016-08-24 2025-12-01 Teneobio Inc Transgenic non-human animals producing modified heavy chain-only antibodies
FI4050034T3 (fi) 2016-09-14 2024-06-10 Teneoone Inc Cd3:een sitoutuvia vasta-aineita
JP7265476B2 (ja) * 2016-11-22 2023-04-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｆｇｆｒ１を対象とするモノクローナル抗体
WO2018095932A1 (en) * 2016-11-22 2018-05-31 Merck Patent Gmbh Monoclonal antibody directed to fgfr1
NZ754713A (en) 2016-12-21 2025-11-28 Teneobio Inc Anti-bcma heavy chain-only antibodies
NZ755816A (en) * 2017-01-19 2026-03-27 Omniab Inc Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
US11427642B2 (en) 2017-06-20 2022-08-30 Teneoone, Inc. Anti-BCMA heavy chain-only antibodies
IL271194B2 (en) 2017-06-20 2024-10-01 Teneobio Inc Anti-bcma heavy chain-only antibodies
WO2019126756A1 (en) * 2017-12-22 2019-06-27 Teneobio, Inc. Heavy chain antibodies binding to cd22
EP3752530A1 (en) 2018-02-14 2020-12-23 ABBA Therapeutics AG Anti-human pd-l2 antibodies
WO2019190922A1 (en) 2018-03-24 2019-10-03 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
MX2020012081A (es) 2018-05-11 2021-04-28 Wuxi Biologics Shanghai Co Ltd Anticuerpos totalmente humanos contra ox40, metodo para preparar los mismos y su uso.
US12012461B2 (en) 2018-05-16 2024-06-18 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
MA52772A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations
US11603405B2 (en) 2018-05-24 2023-03-14 Janssen Biotech, Inc. Anti-CD3 antibodies and uses thereof
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
EP3927832A4 (en) 2019-02-18 2022-11-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS
JP7776987B2 (ja) 2019-04-05 2025-11-27 テネオバイオ， インコーポレイテッド Ｐｓｍａに結合する重鎖抗体
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
KR20220040483A (ko) 2019-07-26 2022-03-30 얀센 바이오테크 인코포레이티드 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는 단백질 및 이의 용도
BR112022001331A2 (pt) 2019-07-26 2022-06-14 Janssen Biotech Inc Receptor quimérico de antígeno (car) anti-hk2
US11760801B2 (en) 2019-09-27 2023-09-19 Janssen Biotech, Inc. Anti-CEACAM antibodies and uses thereof
US20210130440A1 (en) 2019-10-03 2021-05-06 Janssen Biotech, Inc. Methods for producing biotherapeutics with increased stability by sequence optimization
JP7726881B2 (ja) 2019-12-02 2025-08-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用
AU2021263448B2 (en) 2020-04-29 2026-02-05 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
CN116249548A (zh) 2020-05-11 2023-06-09 詹森生物科技公司 用于治疗多发性骨髓瘤的方法
CN116249714A (zh) 2020-05-27 2023-06-09 詹森生物科技公司 包含cd3抗原结合结构域的蛋白质及其用途
KR20230018439A (ko) 2020-06-02 2023-02-07 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물
JP2023536818A (ja) 2020-07-29 2023-08-30 ヤンセン バイオテツク，インコーポレーテツド Ｈｌａ－ｇ抗原結合ドメインを含むタンパク質及びそれらの使用
CA3187680A1 (en) 2020-09-11 2022-03-17 Yashu Liu Identification and production of antigen-specific antibodies
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
CA3205707A1 (en) 2021-01-27 2022-08-04 Fei Shen Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
IL312503A (en) 2021-11-03 2024-07-01 Janssen Biotech Inc Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
WO2023144723A1 (en) 2022-01-26 2023-08-03 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
KR20250071257A (ko) 2022-09-21 2025-05-21 씨젠 인크. Cd137 및 cd228에 특이적인 신규한 융합 단백질
WO2024064714A2 (en) 2022-09-21 2024-03-28 Seagen Inc. Antibodies that bind cd228
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en) 2024-08-06 2026-02-12 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977081A (en) 1987-05-04 1990-12-11 Adi Diagnostics, Inc. Stable rabbit-mouse hybridomas and secretion products thereof
WO1992001043A1 (en) 1990-07-10 1992-01-23 Nkk Corporation Hybridoma which produces avian specific immunoglobulin g
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
ATE300615T1 (de) * 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0583980A1 (en) 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
JPH08140528A (ja) * 1993-12-03 1996-06-04 Genpharm Internatl Inc 異種抗体を産生することができるトランスジェニック非ヒト動物
WO1997016537A1 (en) 1995-10-30 1997-05-09 Spectral Diagnostics, Inc. Stable chicken b-cell line and method of use thereof
US5716081A (en) 1996-03-11 1998-02-10 Automotive Products (Usa), Inc. Spring clip for quick connect coupling
EP1500329B1 (en) * 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
SI2311874T1 (sl) 2004-07-22 2017-12-29 Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics Vezavne molekule
NZ554824A (en) * 2004-10-22 2010-10-29 Revivicor Inc Porcines that lack endogenous antibody chains and express exogenous immunoglobulins
TWI404727B (zh) 2006-01-25 2013-08-11 荷蘭鹿特丹Ｅｒａｓｍｕｓ大學醫學中心 對偶基因排除
AU2007235496B2 (en) * 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
DK2602323T3 (da) * 2007-06-01 2018-04-16 Open Monoclonal Tech Inc Sammensætninger og fremgangsmåder til hæmning af endogene immunglobingener og frembringelse af transgene, humane, idiotypiske antistoffer
BR112012000536A2 (pt) * 2009-07-08 2020-08-11 Kymab Limited métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
AU2011266843C9 (en) * 2010-06-17 2018-03-01 Kymab Limited Animal models and therapeutic molecules
WO2012063048A1 (en) 2010-11-08 2012-05-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination

Also Published As

Publication number Publication date
US9475859B2 (en) 2016-10-25
HRP20201160T4 (hr) 2024-10-11
KR20150094720A (ko) 2015-08-19
NZ749259A (en) 2020-09-25
EP4269602A2 (en) 2023-11-01
FI3653049T3 (fi) 2023-11-02
HUE050930T2 (hu) 2021-01-28
PT2931030T (pt) 2020-08-03
EP3653049B1 (en) 2023-09-13
EP2931030A2 (en) 2015-10-21
IL279716B1 (en) 2026-04-01
KR102239125B1 (ko) 2021-04-12
HUE064063T2 (hu) 2024-02-28
DK2931030T3 (da) 2020-08-03
WO2014093908A2 (en) 2014-06-19
FI2931030T4 (fi) 2024-04-22
CY1123215T1 (el) 2021-12-31
KR20210040189A (ko) 2021-04-12
LT3653049T (lt) 2023-11-10
US20170174770A1 (en) 2017-06-22
HRP20231356T1 (hr) 2024-02-16
AU2013358958A1 (en) 2015-07-09
EP3653049A1 (en) 2020-05-20
IL239300A0 (en) 2015-07-30
EP4269602A3 (en) 2023-12-27
EP2931030B2 (en) 2024-01-17
JP6705650B2 (ja) 2020-06-03
WO2014093908A3 (en) 2014-10-16
SI3653049T1 (sl) 2024-02-29
JP2016505257A (ja) 2016-02-25
PL2931030T5 (pl) 2024-06-10
SG11201504676VA (en) 2015-07-30
ES2813609T3 (es) 2021-03-24
US10385132B2 (en) 2019-08-20
EP2931030B1 (en) 2020-04-29
CN104994729A (zh) 2015-10-21
ES2813609T5 (es) 2024-08-09
CN110042105A (zh) 2019-07-23
PT3653049T (pt) 2023-11-14
IL239300B (en) 2021-01-31
IL279716A (en) 2021-01-31
CA2895144C (en) 2024-04-16
SI2931030T2 (sl) 2024-06-28
KR20220041953A (ko) 2022-04-01
CN104994729B (zh) 2019-01-11
PL3653049T3 (pl) 2024-02-26
SI2931030T1 (sl) 2020-10-30
AU2018223041A1 (en) 2018-09-20
HRP20201160T1 (hr) 2020-12-11
US20150113668A1 (en) 2015-04-23
DK3653049T5 (da) 2024-08-26
CA2895144A1 (en) 2014-06-19
AU2018223041B2 (en) 2020-06-25
LT2931030T (lt) 2020-11-10
AU2013358958B2 (en) 2018-09-20
PL2931030T3 (pl) 2021-03-22
CN110042105B (zh) 2023-03-28
ES2963516T3 (es) 2024-03-27
NZ709608A (en) 2020-09-25
DK3653049T3 (da) 2023-11-13

Similar Documents

Publication Publication Date Title
DK2931030T4 (da) Polynukleotider, der koder for graver-antistoffer med humane idiotyper, og dyr, der omfatter disse
CL2015001924A1 (es) Anticuerpos anti-pdgfr-beta y usos relacionados.
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
DK2925782T3 (da) Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK3308641T3 (da) Immundeficient genmodificeret gnaver og fremgangsmåder til anvendelse deraf
DK3079719T3 (da) ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
LT3473714T (lt) Polipeptidai, pasižymintys transgalaktozilinimo aktyvumu
DK3683235T3 (da) Anti-IL-33-antistoffer og anvendelser deraf
DK3071593T3 (da) Modificerede humane t-celle-receptorer med høj affinitet
BR112014032227A2 (pt) dispositivo e método de decodificação.
FI20155065A7 (fi) Monikäyttölaite eläimen hoitoon
BR302013006798S1 (pt) Configuração aplicada em halter.
HUE049012T2 (hu) Antitestek S. aureus felszíni determinánsok ellen
EP2922564A4 (en) ONCOLYTIC POLIOVIRUS FOR HUMAN TUMORS
HUE053561T2 (hu) Állatõrzõ kerítés és eljárás annak összeszerelésére
PL3004167T3 (pl) Białka wiążące antygen receptora onkostatyny m
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf
BR112014004128A2 (pt) dispositivo e método de decodificação, dispositivo e método de codificação, e, programa
DK3434614T3 (da) Aftageligt dækningsapparat med flere dele og tilhørende
BR112014004127A2 (pt) dispositivo e método de decodificação, programa, e, dispositivo e método de codificação
DK3016547T3 (da) Dyrebarriere og fremgangsmåde
DK2814843T3 (da) IL-ß-NEUTRALISERENDE HUMANE MONOKLONALE ANTISTOFFER
EP3754986C0 (en) IMAGE DECODING DEVICE, METHOD AND PROGRAM
DK2953957T3 (da) Modificerede glycolipider og fremgangsmåder til fremstilling og brug af disse
DK2895600T3 (da) Ube2t-peptider og vacciner, der indeholder disse